Another major healthcare company has agreed to acquire a fledgling biopharma company, and biopharma investors are hoping that an increase in dealmaking will help boost the stocks of the sector in general.On Tuesday, Eli Lilly agreed to buy DICE Therapeutics for $48 per share in